Christine Lebrun-Frenay

May 15, 2024 | journals.sagepub.com | Christine Lebrun-Frenay |Darin T. Okuda

Get full access to this articleView all access and purchase options for this article. Data availability statementData sharing not applicable to this article as no datasets were generated or analyzed during the current study. References1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162–173. 2. Solomon AJ, Arrambide G, Brownlee WJ, et al.

Apr 15, 2024 | journals.sagepub.com | Darin T. Okuda |Christine Lebrun-Frenay

IntroductionThe ancient Greek physician Hippocrates emphasized the importance of observation and clinical findings to understand the basis of disease and facilitate early intervention. Identifying the exact cause and timing of the development of clinical manifestations that follow remain elusive for many disorders, including multiple sclerosis (MS), a heterogeneous autoimmune condition affecting myelin and axons within key anatomical structures within the central nervous system (CNS).

Aug 21, 2023 | jamanetwork.com | Christine Lebrun-Frenay |Université Cote d’Azur |Aksel Siva |Maria Pia Sormani

Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial Key PointsQuestion  Is it possible to prevent multiple sclerosis with a disease-modifying treatment in people with preclinical demyelinating disease?

Jun 9, 2023 | journals.sagepub.com | Susana Otero-Romero |Christine Lebrun-Frenay |Saúl Reyes |Maria amato

AbstractBackground:With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategyObjective:To develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs). Methods:This work was conducted by a multidisciplinary working group using formal consensus methodology.

Jun 9, 2023 | journals.sagepub.com | Susana Otero-Romero |Christine Lebrun-Frenay |Saúl Reyes |Maria amato

IntroductionOver the last years, there has been a relevant change in the long-term prognosis of people with multiple sclerosis (pwMS), mainly due to the regulatory approval of a range of highly active immunotherapies with mechanisms of action that include alteration of lymphocyte trafficking, lymphocyte depletion and disruption of lymphocyte replication.